Amount evidence has indicated that PAK1 is substantially overexpressed in various cancers, including breast cancer, hepatocellular carcinoma, pancreatic cancer, lung cancer and cutaneous T cell lymphoma [8–11]. Here, PAK1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.